—New Company Is Developing Growth Hormone-Releasing Hormone Therapeutics Initially Targeting Resistant Prostate Cancer and Coronary Heart Disease—
—Biscayne Scientific Advisor and Nobel Laureate Dr. Andrew V. Schally Has Discovered Multiple Successful Drugs—
MIAMI, Jan. 18, 2013 -- Biscayne Pharmaceuticals, Inc. today announced that it has closed a $1.5 million financing. The new company is developing novel growth hormone-releasing hormone (GHRH) drugs based on recent discoveries by the company's scientific advisor, Dr. Andrew V. Schally , a world-renowned drug researcher and Nobel laureate who pioneered the field of hypothalamic peptide drugs. Biscayne also announced that it has exclusively licensed intellectual property from the University of Miami that includes worldwide rights to the Schally GHRH technology, including GHRH antagonists with potential in the treatment of cancer and GHRH agonists with potential as an innovative approach to treating heart disease.
Dr. Schally, the Distinguished Leonard M. Miller Professor of Pathology & Professor of Hematology and Oncology at the University of Miami Miller School of Medicine, was awarded the Nobel Prize in Medicine for his breakthrough work on peptide hormones and the brain. He has had a prolific career as the inventor of many important new drugs, having discovered a number of agents based on luteinizing hormone-releasing hormone (LHRH). Products stemming from his discoveries continue as mainstays of therapy in oncology and gynecology and generate billions of dollars in sales each year.
Dr. Schally commented, "New GHRH analogs are the latest in a line of synthetic hypothalamic hormones with potential as novel therapeutics for multiple diseases. A number of our GHRH antagonists have demonstrated promising preclinical activity against many types of cancer, including hard-to-treat prostate cancer, and our GHRH agonists may represent a wholly new regenerative approach to treating heart disease. GHRH analogs may also have utility in other conditions, such as Alzheimer's disease. I look forward to working with the accomplished team at Biscayne to advance our rich pipeline of drug candidates."
Biscayne's lead GHRH antagonist is in preclinical development initially for the treatment of castrate-resistant prostate cancer (CRPC), a particularly lethal form of prostate cancer affecting 30,000 new patients each year in the US. The GHRH antagonists work through a novel pathway that reduces the levels of hormones fueling the growth of tumors. In animal studies, these antagonists have shown promising anti-tumor activity and were synergistic with chemotherapy. The company believes that GHRH antagonists may have therapeutic potential in many other types of tumors, including breast, brain, lung, colon and skin.
Biscayne's lead GHRH agonists have demonstrated a unique capacity to repair the heart following ischemic injury, such as a heart attack, and are in preclinical development for the repair of damaged cardiac tissue. GHRH agonists directly activate GHRH receptors in the heart, stimulating tissue healing through a variety of mechanisms. GHRH agonists may represent a new class of therapy for cardiac conditions that presently afflict millions of patients worldwide.
In preclinical studies, GHRH agonists improved both cardiac structure and function and reduced myocardial infarct size and scarring, thereby reducing the chance of future heart failure. Joshua M. Hare , MD, a scientific co-founder of Biscayne, who is the Louis Lemberg Professor of Medicine in the University of Miami Health System, is working with Dr. Schally to develop the GHRH technology for coronary heart disease.
Dr. Hare noted, "Despite the many advances in cardiovascular therapy, millions of patients are disabled and ultimately killed each year from cardiac damage due to coronary heart disease. Our GHRH agonists represent a unique and powerful approach aimed at developing drugs to reduce and repair this damage. I look forward to working with the Biscayne team to rapidly develop this approach for testing in patients."
The Reich Group, an investment firm based in Miami Beach, Florida, led the financing. Samuel Reich , Managing Partner of The Reich Group and formerly a founder and Executive Vice President of Acuity Pharmaceuticals and OPKO Health, is joining Biscayne Pharmaceuticals as Chief Executive Officer and Chairman of the Board of Directors.
Reich noted, "The opportunity to work with Biscayne's outstanding scientific founders to develop drugs with breakthrough potential in intractable diseases was one I had to take, and I am delighted to be leading this exciting new company. We will apply the proceeds of this first financing to further develop our infrastructure and progress our initial drug candidates through preclinical development."
Biscayne's technology is licensed from the University of Miami. Norma Sue Kenyon , Chief Innovation Officer and Vice Provost of the University, commented, "The University of Miami is committed to working with our partners to ensure that our scientific discoveries emerge from the lab to make a positive difference in the world. We are very pleased that these innovative technologies developed by some of our most accomplished medical researchers are being developed and commercialized by the experienced team at Biscayne Pharmaceuticals."
About Biscayne Pharmaceuticals
Biscayne Pharmaceuticals, Inc. is a privately held biopharmaceutical company discovering and developing novel therapies based on growth hormone-releasing hormone (GHRH) analogs. The company's technology stems from the discoveries of Dr. Andrew V. Schally , a Nobel laureate and pioneering endocrine drug developer. Biscayne's lead compounds include GHRH antagonists in development for the treatment of cancer, including castrate-resistant prostate cancer, and GHRH agonists for the repair of cardiac damage in heart disease patients. GHRH analogs may also have utility in other conditions, such as Alzheimer's disease. Biscayne's technology is licensed from the University of Miami, and the company is headquartered in Miami, FL.
Media:
Jared Mendel
BLL Partners
(305) 793-7326
Barbara Lindheim
[email protected]
(212) 584-2276
SOURCE Biscayne Pharmaceuticals
PR Newswire (http://s.tt/1yDja)